Form 4: Precision BioSciences Executive Acquires Restricted Stock Units

J. Jefferson Smith, Chief Research Officer of Precision BioSciences, acquired 48,657 restricted stock units on August 22, 2024.

Summary

• On August 22, 2024, J. Jefferson Smith, the Chief Research Officer of Precision BioSciences, acquired 48,657 restricted stock units.
• These restricted stock units represent a contingent right to receive one share of Precision BioSciences' Common Stock each.
• The award vests in three substantially equal annual installments beginning on January 20, 2025, contingent upon Smith's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral-positive signal.

Positives

• The acquisition of restricted stock units by a key executive signals confidence in the company's future.

Future Outlook

The vesting of the restricted stock units is contingent upon the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Industry Context

This is a standard practice for incentivizing and retaining key executives in publicly traded companies, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry.
• Vesting schedules typically range from three to five years, with annual or quarterly vesting intervals.
• The size of the grant is generally determined by the executive's role, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that the company is incentivizing its key executives to remain with the company and contribute to its success.
• Employees may see this as a sign of stability and opportunity within the company.

Key Dates